The vitamin K antagonist Coumetarol (Dicumoxane) is effective in both models after oral treatment but inhibits thrombus formation more strongly in the arterio-venous shunt model. Treatment with Coumetarol in a dose of 25 mg/kg p.o. twice daily for 2 days results in a significant reduction in thrombus weight by 50% in the venous stasis model and by 75% in the arterio-venous shunt model. In both experiments, the coagulation time as measured by the Thrombotest is prolonged to the same extent.

维生素K拮抗剂Coumetarol在口服治疗后，在两种模型中均显示出有效性，尤其在动脉连接模型中展现出更强的血栓抑制效果。Coumetarol的治疗剂量为25 mg/kg，通过口服给药。在静脉暂停模型中，连续两天每天两次给药可使血栓重量显著减少50%；而在动脉裂开的分流模型中，血栓重量则显著减少了75%。[1]